Specify a stock or a cryptocurrency in the search bar to get a summary
Kiora Pharmaceuticals Inc
7EY0Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials indicated for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, currently under phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; KIO-101, an eye drop for the treatment of ocular presentation of rheumatoid arthritis; and KIO-201, an eye drop for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. It has commercialization agreement with 4SC Discovery GmbH, for KIO-101; and collaboration agreement with Théa Open Innovation for the development KIO-301. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California. Address: 332 Encinitas Boulevard, Encinitas, CA, United States, 92024
Analytics
WallStreet Target Price
30.33 USDP/E ratio
0.2238Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 7EY0
Dividend Analytics 7EY0
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 7EY0
Stock Valuation 7EY0
Financials 7EY0
Results | 2019 | Dynamics |